Mayo Clinic News Network

News Resources

Bob Nellis (@bobnellis)

Activity by Bob Nellis

Bob Nellis (@bobnellis) posted · Tue, Mar 24 9:22am · View  

Mayo Clinic Center for Tuberculosis Launches New TB Journal

The Mayo Clinic Center for Tuberculosis,  a regional training and consultation center at Mayo Clinic's campus in Rochester, Minn, is today launching a new medical journal, the Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. The online journal is published by Elsevier.cover of Clinical Tuberculosis magazine

“We believe that the Journal of Clinical Tuberculosis and Other Mycobacterial Diseases fills an unmet need by providing a platform for the dissemination of the results of clinically relevant research,” say the editors in their inaugural editorial for the publication. They also cite the continue spread of tuberculosis as a global health problem, making it the second greatest cause of death from infectious diseases after HIV.

“We are very excited that we are launching this journal on World TB Day and hope that it will effectively advance new knowledge that will ultimately help end this terrible disease,” says Editor-in-Chief Zelalem Temesgen, M.D [Za-La-Lum Tah-mezg-in]. Two other Mayo Clinic physician-researchers, Stacey Rizza, M.D. and John Wilson, M.D., will serve as associate editors. All three are members of the Division of Infectious Diseases at Mayo Clinic and members of the tuberculosis center. An editorial board composed of leading experts in the field from around the globe has already been established to help advance the journal's mission.

MEDIA CONTACT: Bob Nellis, Mayo Clinic Public Affairs, 507-284-5005, Email: newsbureau@mayo.edu [...]

Click here to view the rest of the post

Login here to comment.

Bob Nellis (@bobnellis) posted · Mon, Mar 9 12:35pm · View  

Mayo Clinic and Collaborators Find New Class of Drugs that Reduces Aging in Mice

A new class of drugs identified and validated by Mayo Clinic researchers along with collaborators at Scripps Research Institute and others, clearly reduces health problems in mice by limiting the effect of senescent cells — cells that contribute to frailty and diseases associated with age. The researchers say this is a first step toward developing similar treatments for aging patients. Their findings appear today in the journal Aging Cell.

 “If translatable to humans — which makes sense as we were using human cells in many of the tests – this type of therapy could keep the effects of aging at bay and significantly extend the healthspan of patients,” says James Kirkland, M.D., Ph.D., head of the Mayo Clinic Kogod Center on Aging and senior author of the study.two senior citizens, elderly couple walking down a road or path

 The drugs — called senolytics — selectively kill senescent cells without harming nearby cells and tissue, to reduce heart and vascular problems, muscle weakness, osteoporosis, and neurological problems. Senescent cells are cells that appear with aging and at sites of many age-related diseases. They produce factors that can damage the cells and tissues around them and at a distance, amplifying their effects. In many examples, the drugs caused significant and visible reduction of multiple conditions after just one dose – and remained therapeutic for up to seven months. The researchers say that this long lasting effect is consistent with a change in cellular or tissue composition.

MEDIA CONTACT: Bob Nellis, Mayo Clinic Public Affairs, 507-284-5005, Email: newsbureau@mayo.edu [...]

Click here to view the rest of the post

Login here to comment.

Bob Nellis (@bobnellis) posted · Wed, Jan 21 2:46pm · View  

Mayo Clinic to host Science Conference for area students on Jan. 27

Researchers working in labMayo Clinic researchers have invited approximately 200 area eighth grade and high school students to the 16th Biennial Celebration of Research, a daylong conference for students interested in learning about careers in science.

The keynote address, "Harnessing Viruses to Attack Cancer," will be presented by Eva Galanis, M.D., a professor of oncology and chair of the Department of Molecular Medicine at Mayo Clinic. This year's theme, "Going Viral," pertains to Dr. Galanis’ research and clinical efforts on using modified viruses to develop novel therapeutics for cancer treatment.

Students are scheduled to attend from Albert Lea, Altura, Austin, Blooming Prairie, Caledonia, Chatfield, Dover, Elgin, Eyota, Faribault, Grand Meadow, Houston, Kasson, Kenyon, Lanesboro, Lewiston, Lyle, Mantorville, Mazeppa, Millville, Northfield, Owatonna, Peterson, Pine Island, Plainview, Rochester, Rushford, Southland, Stewartville, Winona and Zumbrota. [...]

Click here to view the rest of the post

Login here to comment.

Bob Nellis (@bobnellis) posted · Thu, Dec 4 2014 · View  

Mayo Clinic’s Discovery’s Edge Launches Android Platform

DE_CoverROCHESTER, Minn. — Android users no longer have to miss out on all the research discoveries coming from Mayo Clinic. The newest issue of Discovery’s Edge, Mayo Clinic’s research magazine, is now available on all Android devices, as well as the iPad, online and in print. Research news from Mayo Clinic — however, whenever and wherever you want to read it.

Highlights in this issue explore the past, present and future of Mayo Clinic research, including:

Biomarker discovery: Staying one step ahead of cancer

Read about a 12-month snapshot of how four researchers combined their talents to discover biomarkers that could help specific patients with difficult medical issues. In that time span, the Biomarker Discovery Program — part of Mayo Clinic’s Center for Individualized Medicine — found 32 biomarkers using custom algorithms and other innovative approaches that physicians can use to aid patients.

Mayo Clinic plugs into drug discovery

Collaboration is also the story of Mayo Clinic’s latest partnership — with Sanford-Burnham Medical Research Institute. Two organizations looking for just the right counterpart to meet a strategic need found each other at just the right time to fast-track drug discovery for Mayo patients.

Next generation: Developing tomorrow’s biomedical researchers

The path to becoming a biomedical researcher is not for the faint of heart. This issue’s cover story takes a glimpse at three scientists-in-training at Mayo Graduate School and the obstacles they are facing, both personal and professional, as they strive toward careers in research. [...]

Click here to view the rest of the post

Login here to comment.

Bob Nellis (@bobnellis) posted · Thu, Nov 13 2014 · View  

Mayo Clinic Researchers: TNF Inhibitors May Increase Cancer Risk in the Eye

Jose Pulido, M.D., senior author of the study in Mayo Clinic Proceedings.

Jose Pulido, M.D., senior author of the study in Mayo Clinic Proceedings.

ROCHESTER, Minn. — One of the family of drugs prescribed for rheumatoid arthritis and other inflammatory conditions is called TNF inhibitors. They act by dampening part of the immune system called tumor necrosis factor (TNF). In one of the balancing acts of medicine, the anti-inflammatory action of the drug also increases the risk for other conditions, in this case, a rare form of eye cancer, uveal melanoma. Mayo Clinic researchers make the case and alert physicians in an article in Mayo Clinic Proceedings.

 Mayo researchers studied three patients — two women and a man — who were treated for inflammatory disease and developed melanoma tumors in one eye within a year to two of taking TNF inhibitors. While this type of condition is probably rare, according to the researchers, there might be an increased risk if the patient has a pre-existing nevus (freckle of the eye). The women had inflammatory bowel disease; the man had rheumatoid arthritis. The studies occurred between 2009 and 2013.

Researchers say that patients considered for treatment with TNF inhibitors should first be given an eye exam to determine eye health, and any with existing conditions, such as choroidal nevus (lesions on the eye), should be monitored regularly to determine if any issues are developing.

MEDIA CONTACT:  Robert Nellis, Mayo Clinic Public Affairs, 507-284-9258, newsbureau@mayo.edu [...]

Click here to view the rest of the post

Login here to comment.

Bob Nellis (@bobnellis) posted · Tue, Nov 4 2014 · View  

Minnesota Partnership Announces Scientific Infrastructure Awards

University of Minnesota Research Partnership Logo

ROCHESTER and MINNEAPOLIS, Minn. — The Minnesota Partnership for Biotechnology and Medical Genomics has awarded $2.5 million to four teams of researchers to support scientific infrastructure used in collaborations between existing researchers at the University of Minnesota and Mayo Clinic. The funding must be used for equipment, software or other technology essential to specific research projects and must be mutually available to the project participants at both institutions. This year’s awards will help investigators target topics ranging from heart disease and cancer to drug development and the microbiome, all key focus areas of research in Minnesota. [...]

Click here to view the rest of the post

Login here to comment.

Bob Nellis (@bobnellis) posted · Tue, Nov 4 2014 · View  

Mayo Clinic Researchers Discover Genetic Markers for Alcoholism Recovery

ROCHESTER, Minn. — In an international study, Mayo Clinic researchers and collaborators have identified genetic markers that may help in identifying individuals who could benefit from the alcoholism treatment drug acamprosate. The findings, published in the journal Translational Psychiatry, show that patients carrying these genetic variants have longer periods of abstinence during the first three months of acamprosate treatment.Bank of test tubes in research laboratory

Acamprosate is a commonly prescribed drug used to aid patients in recovery from alcoholism. Mayo researchers studied the association between variation in candidate genes and the length of sobriety in alcohol-dependent patients treated with acamprosate in community-based programs. They found that, when other environmental and physiological factors were considered, patients with the common allele of the genetic variant rs2058878 located in the GRIN2B gene, stayed sober more days than those with a variant allele of the same polymorphism. This finding was replicated in a sample of alcohol-dependent patients treated with acamprosate in a study conducted by collaborators from Germany.

[...]

Click here to view the rest of the post

Login here to comment.

Bob Nellis (@bobnellis) posted · Tue, Sep 9 2014 · View  

Multi-Institutional Research Team Measures Multiple Morbidities

Journalists: Sound bites with Dr. Rocca are in the downloads.

ROCHESTER, Minn. — A collaborative study by researchers from Mayo Clinic, Olmsted Medical Center and Johns Hopkins University has measured multimorbidity — multiple diseases or medical conditions co-occurring in a single patient — and has determined which combinations of medical conditions are more prevalent by age, sex, and race/ethnicity in a geographically-defined Midwestern population. Investigators say that their findings, published in Mayo Clinic Proceedings, are valuable in light of the aging population, the need to plan and prioritize health care interventions, and have broad implications for clinical research.

group of people standing together representing diversity

Using a list of 20 medical conditions developed by the U.S. Department of Health and Human Services, the research team accessed records for over 138,000 persons who lived in Olmsted County, Minnesota, during 2010 via the Rochester
Epidemiology Project. They concluded that multimorbidity is fairly common in the general population; it increases steeply with older age; has different combinations in men and women; and varies by race/ethnicity.

MEDIA CONTACT: Robert Nellis, Mayo Clinic Public Affairs, 507-284-5005, newsbureau@mayo.edu

[...]

Click here to view the rest of the post

Login here to comment.

Load More    

Loading information...